Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New Two-Drug attack on tough brain cancers

NCT ID NCT07468136

Summary

This study is testing a new combination of two drugs, retifanlimab and DFMO, for people with aggressive brain tumors (high-grade gliomas) that have started growing again. The main goals are to find the safest dose of DFMO to use with retifanlimab and to see if the combination changes the immune cells around the tumor. The trial will enroll about 33 adults who are scheduled for surgery to remove their tumor.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT GLIOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Mayo Clinic in Rochester

    Rochester, Minnesota, 55905, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.